Writing Homework Help

HI I HAVE TO REPLY TO THIS POST

The Mechanism of action of a Biologic drug is as follows the biologics act to inhibit key inflammatory molecules that are thought to be involved in the pathogenesis of these chronic inflammatory disorders as well as physiologic immune responses.

Adalimumab is a fully human IgG1 monoclonal antibody that specifically binds to tumor necrosis factor (TNF)-alpha and is administered by subcutaneous injection. The mechanism of action is based on both the neutralization of TNF-alpha bioactivity and the induction of apoptosis of TNF-expressing mononuclear cells. Humira (adalimumab) is a tumor necrosis factor (TNF) blocker that reduces the effects of a substance in the body that can cause inflammation. (Bansal 2021)

The advantages Humira has are that It has good efficacy in psoriasis and psoriatic arthritis. Also, Adalimumab is used to reduce pain and swelling due to certain types of arthritis (such as rheumatoid, psoriatic, juvenile idiopathic, ankylosing spondylitis). This medication is also used to treat certain skin disorders (such as plaque-type psoriasis, hidradenitis suppurativa).

The disadvantages are that it is an immune system suppressant and can cause serious infections as well as Nervous system issues and lead to Heart failure when used long term and can lead to Lymphoma cancer.

One of the main chronic illnesses Humira is used for is Crohn’s Disease, HUMIRA is a medication called a TNF blocker. It works by binding to TNF molecules and blocking them. This helps reduce the inflammation that can lead to symptoms of Crohn’s disease or ulcerative colitis. Biologic drugs like Humira help reduce inflammation and manage symptoms of Crohn’s by blocking the inflammatory reactions in your body. This can help ease Crohn’s symptoms and assist with disease remission. ( Bansal P 2021)

Nonpharmacological treatment options that can be offered to patients with Crohn’s diseases are Probiotics, Prebiotics, Fish Oil and Acupuncture

References

Benjamin O, Bansal P, Goyal A, et al. Disease-Modifying Anti-Rheumatic Drugs (DMARD) [Updated 2021 Jul 6]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan

Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L. Crohn’s disease. Lancet. 2017 Apr;389(10080):1741–55.

Maaser C, Sturm A, Vavricka SR, Kucharzik T, Fiorino G, Annese V, et al.; European Crohn’s and Colitis Organisation [ECCO] and the European Society of Gastrointestinal and Abdominal Radiology [ESGAR]. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: initial diagnosis, monitoring of known IBD, detection of complications. J Crohn’s Colitis. 2019 Feb;13(2):144–64.